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licenses/by/4.0/).Abstract Although biliary tract cancers (BTCs) are known to have an inflammatory compo-
nent, a detailed characterisation of immune-related transcripts has never been performed. In
these studies, nCounter PanCancer Immune Profiling Panel was used to assess the expression
of 770 immune-related transcripts in the tumour tissues (TTs) and matched adjacent tissues
(ATs) of resected BTCs. Cox regression analysis and KaplaneMeier methods were used to
correlate findings with relapse-free survival (RFS). The first analysis in the TT and AT of
an exploratory set (n Z 22) showed deregulation of 39 transcripts associated with T-cell; CCA, cholangiocarcinoma; ECC, extrahepatic CCA; ICC, intrahepatic CCA; GBC, gallbladder cancer;
tissue; AT, adjacent tissue; FFPE, formalin fixed paraffin embedded; PBK, PDZ binding kinase; CTLA4,
B1, transforming growth factor beta; IL-6, interleukin 6; CD80, cluster of differentiation 80; IP, immune
R0, clear resection margins; POLR2A, RNA polymerase II subunit A; IPA, ingenuity pathway analysis;
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M. Ghidini et al. / European Journal of Cancer 86 (2017) 158e165 159activation. Risk of recurrence was associated with a greater number of genes deregulated in
AT in comparison to TT. Analysis in the whole set (n Z 53) showed a correlation between
AT cytotoxic T-lymphocyte antigen-4 (CTLA4) expression and RFS, which maintained statis-
tical significance at multivariate analysis. CTLA4 expression correlated with forkhead box P3
(FOXP3) expression, suggesting enrichment in T regulatory cells. CTLA4 is known to act by
binding to the cluster of differentiation 80 (CD80). No association was seen between AT CD80
expression and RFS. However, CD80 expression differentiated prognosis in patients who
received adjuvant chemotherapy. We showed that the immunomodulatory transcriptome is
deregulated in resected BTCs. Our study includes a small number of patients and does not
enable to draw definitive conclusions; however, it provides useful insights into potential tran-
scripts that may deserve further investigation in larger cohorts of patients.
Transcript Profiling: Nanostring data have been submitted to GEO repository: GSE90698 and
GSE90699.
ª 2017 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC
BY license (http://creativecommons.org/licenses/by/4.0/).Table 1
Demographics of patients.
Characteristics Exploratory set Entire set
Number (%) Number (%)
Patients 22 53
Gender
Female 10 (45%) 23 (43%)
Male 12 (55%) 30 (57%)
Age
Median (years) [range] 65 [41e76] 63 [38e77]
Tumour site
ICC 4 (18%) 21 (40%)
ECC 10 (45%) 24 (45%)
GBC 8 (37%) 8 (15%)
T stage
T1 1 (5%) 8 (15%)
T2 9 (40%) 29 (55%)
T3 7 (32%) 11 (21%)
T4 5 (23%) 5 (9%)
N stage
N0 11 (50%) 24 (45%)
N1 11 (50%) 18 (34%)
Nx 0 (0%) 11 (21%)
Resection margins
Negative (R0) 17 (77%) 47 (89%)
Positive (R1) 5 (23%) 6 (11%)1. Introduction
Biliary tract cancers (BTCs) arise from the epithelium of
bile ducts and gallbladder [1]. Ninety percent of BTCs
are adenocarcinomas, also called cholangiocarcinomas
(CCAs). Although intrahepatic (ICC) and extrahepatic
(ECC) CCAs harbour at least partially different mo-
lecular features, the clinical management of BTC does
not differ according to the subtypes [2e4]. In phase III
clinical trials, ICC, ECC and gallbladder cancers are
grouped together as BTCs [5,6].
Surgery is the only curative treatment modality in
BTCs. However, the 5-year survival rate for patients
with resected BTCs is only 10e50% [7,8]. Therefore,
consideration of adjuvant therapy is justified. Never-
theless, the BILCAP study suggests that adjuvant
chemotherapy can improve the outcome of resected
BTCs [9]. It is likely that the discovery of prognostic
factors associated with the biological aggressiveness of
these tumours will guide the post-surgical management
of BTCs. Recent evidence suggests that the host immune
response modulates the effect of chemotherapy in solid
tumours [10,11]. Inflammation and immune modulation
are recognised as driving forces in the pathogenesis of
BTCs [2,12e18]. However, detailed immune profiling of
tumour and peritumoural areas has not been performed
in BTCs. In this study, we aimed at characterising the
deregulation of immune-related transcripts in resected
BTCs and exploring their potential as prognostic
markers.Adjuvant chemotherapy
Yes 11 (50%) 33 (62%)
No 11 (50%) 20 (38%)
Recurrence
Yes 15 (68%) 40 (75%)
No 7 (32%) 13 (25%)
Follow-up
Median RFS (months) [range] 13.1 [0.33e63.3] 17.8 [0.33e91.73]
ICC, intrahepatic cholangiocarcinoma; ECC, extrahepatic chol-
angiocarcinoma; GBC, gallbladder cancer; RFS, relapse-free survival.2. Patients and methods
2.1. Patient population
We assessed a set of 53 patients with resected BTCs
treated at the Humanitas Clinical and Research Center,
Rozzano (Milan, Italy) and the University Hospital ofPadua (Padua, Italy). The study protocol was given
ethical approval by Institutional Review Boards. All
patients underwent curative surgery (Table 1). Data
collection was performed retrospectively. Relapse-free
survival (RFS) was used as end-point of the study.
The first analysis was performed in an exploratory
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were performed in tumour (TTs) and adjacent tissues
(ATs). Extended analyses were carried out in the whole
set of patients (n Z 53) by performing nanostring ana-
lyses in the AT only. mRNA expression profiling was
analysed with a commercially available nCounter Pan-
Cancer Immune Profiling Panel from NanoString
Technologies (Seattle, WA, USA), as per manufac-
turer’s instructions.
2.22.2. Statistical analysis
RFS was defined as the time between surgery and
radiological evidence of tumour relapse. RFS was cho-
sen as end-point of the study to avoid bias related to
different treatments in the metastatic setting. Patients
alive and without evidence of tumour relapse at the time
of the analysis were censored at last follow-up. The
KaplaneMeier method was used to calculate survival
estimates, and comparison of the treatment arms was
carried out using a log-rank analysis. Hazard ratios
(HRs) and 95% confidence intervals (CIs) were obtained
by Cox regression. Multivariate Cox regression was used
to assess whether an interaction remained significant
after addition of prognostic variables including tumour
site, T, N, resection margins, adjuvant treatment and
institution. We correlated mRNA expression with clin-
ical indicators dichotomising samples at the median
gene expression in high- versus low-expression group. P
value for statistical significance was set at <0.05. Sta-
tistical analyses were performed by R and GraphPad
Prism 6 (La Jolla, CA, USA), in a blinded fashion by an
external biostatistician.
Further methods can be found in the Supplementary
file.
3. Results
Previous studies suggest that BTCs are inflammatory
cancers associated with derangement of cytokines and
recruitment of immune cells. To investigate if the tran-
scriptomic immune profile is deregulated in BTC, we
started by performing a comprehensive immune
profiling of 770 immune-related transcripts in TT and
AT of a set including 22 resected BTCs. Demographic
characteristics of patients are listed in Table 1. One-
hundred ninety-five transcripts were aberrantly
expressed (109 upregulated and 86 downregulated) in
TT compared with AT (p < 0.05) (Fig. 1A). Of these, 39
transcripts were deregulated >2-fold in TT compared
with AT (Suppl Table 1). Ingenuity Pathway Analysis of
this set of genes showed involvement in the inflamma-
tory response, immune-cell trafficking and T-cell
deregulation (Suppl Table 2). This network includes
genes such as cluster of differentiation 80 (CD80), which
regulates T-cell activation by binding to cytotoxic
T-lymphocyte antigen-4 (CTLA4) (Suppl Fig. 1).Amongst the transcripts deregulated by an average >2-
fold (Suppl Table 1, Fig. 1B), there is PDZ-binding ki-
nase, a kinase produced by lymphokine-activated killer
T-cells, which was previously found to be a CCA-spe-
cific transcript associated with prognosis [19].
It is recognised that deregulation of the immune
system may be a cause of cancer progression by creating
a favourable microenvironment for cancer growth and
escape. Thus, we extended our analysis to genes that
were not differently expressed between cancer and ATs,
hypothesising that genes expressed in the tumour
compartment may reflect enrichment of immune cells
within the tumour content, whereas genes expressed in
the adjacent compartment reflect deregulation of im-
mune infiltrate in the normal tissue that creates a
favourable soil for cancer-cell growth. We began by
analysing the clinical impact of BTC type on survival.
RFS was not statistically different according to tumour
site (Suppl Fig. 2); thus, we grouped our tumour types
together in line with the analyses performed in the major
clinical trials that have generated recommendation for
clinical practice [5,9].
We derived a list of genes, whose expression was
associated with RFS at univariate analysis, and we
shortlisted genes that maintained statistical significance
at multivariate analysis (Suppl Fig. 3). Interestingly,
tumours with high expression of NOTCH1 were signif-
icantly associated with lower RFS (Suppl Fig. 3) as
previously described [20,21]. We observed that risk of
recurrence was associated with a greater number of
genes deregulated in AT in comparison with genes
altered within the TT, suggesting that the inflammator-
yeimmunomodulatory background plays an important
role in BTC development and progression (Suppl
Fig. 3). As much as we do believe that deregulation of
immune transcripts in the TT may deserve further
investigation as prognostic markers; for the purpose of
this study, we decided to focus on the transcripts
deregulated in the peritumoural tissue, given this is an
area of recognised activity of the immune cells that
localise in the peritumoural border [22,23]. Thus, we
extended our nCounter profiling to the AT of the 53
cases of the entire set. Univariate and multivariate an-
alyses were run to identify transcripts that were associ-
ated with RFS (Suppl Table 3). Amongst several genes,
we focussed on those that represented targetable path-
ways. While we have not observed any correlation be-
tween PD1 expression and RFS (Fig. 2), we observed an
inverse correlation between RFS and expression
of CTLA4 (Fig. 2 and Suppl Fig. 4A). Therapeutics are
available to target CTLA4, and therefore we focussed
our attention on this transcript. The relative expression
of CTLA4 did not differ across the different subtypes in
the set of patients for which TT and AT expression was
available (Suppl Fig. 4B and C). CTLA4 maintained its
prognostic value also in the multivariate analysis (Suppl
Table 4). CTLA4 is mainly displayed on activated T
Fig. 1. Immunomodulatory transcripts are deregulated in biliary tract cancers (BTCs). RNA from tumour tissue (TT) and adjacent tissue
(AT) of BTCs of the exploratory set were subjected to nCounter analysis of 770 immune-related transcripts. (A) Heatmap showing
mRNAs deregulated in TT compared with AT (adjusted p < 0.05). (B) Graphic representation of the top 20 transcripts deregulated >2-
fold in TT versus AT (p < 0.05). Each dot represents the log of the ratio between TT and AT for each patient. Positive values indicate
upregulation in TT; negative values indicate downregulation in TT.
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CD86 [24]. We noticed a correlation between CTLA4
expression and FOXP3 expression, suggesting that cases
with high CTLA4 indeed have an enrichment of Tregs
(Suppl Fig. 4D). As CD80 and CD86 co-contribute to
the activation of Treg through interaction with CTLA4,
we looked at the correlation between RFS and CD80
and CD86 expression. Neither CD80 nor CD86 could
differentiate prognosis when all the cases were grouped
together. However, there was a trend for worse survival
for high CD80-AT cases in patients undergoing adju-
vant chemotherapy (Suppl Fig. 5), in line with published
data on the role of Tregs in response to chemotherapy
[10,11]. To further investigate this finding, we examined
the count of CD80-positive cells using immunohisto-
chemistry (IHC). In the subgroup that received adjuvant
chemotherapy, we confirmed that cases with strong AT
CD80 expression had a longer median RFS (28.8
months) compared to cases with negative/mild CD80expression (16.27 months) (HR 3.25 [95% CI:
1.31e15.54; pZ 0.02]; Fig. 3AeC). As this may suggest
a value of CD80 as a biomarker of sensitivity to
chemotherapy, we looked at the effect of adjuvant
chemotherapy in patients with strong CD80 expression
compared to the negative/mild ones. While no advan-
tage was observed for cases with strong CD80 expres-
sion, adjuvant chemotherapy tended to improve RFS in
cases with negative/mild expression of CD80, even
though statistical significance was not reached (Fig. 3D).
We acknowledge that the low numbers in these analyses
do not allow for any definitive conclusion, but we
believe CD80 may be a promising marker to be studied
in larger cohorts.
Given these data suggest that an immunomodulatory
network plays a role in BTC relapse, we searched for a
gene signature that could identify cases with higher risk
of relapse. We derived a gene signature using the 42
genes that were associated to RFS (Suppl Table 3). This
Fig. 2. Cytotoxic T-lymphocyte antigen-4 (CTLA4) is associated with relapse-free survival. (A) CTLA4 mRNA was assessed by nCounter
analysis in the entire set (nZ 53). Cases were divided according to low and high expression of mRNA in the adjacent tissue (AT) (using
median as cut-off). Median overall survival was 16.27 months in cases with high CTLA4 expression, whereas it was 29.53 months in low
CTLA4 cases. (B) PDCD1 mRNA was assessed by nCounter analysis in the entire set. Cases were divided according to low and high
expression of mRNA in the AT (using median as cut-off). RFS, relapse-free survival.
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higher risk of relapse (Suppl Fig. 6). When the predictive
performance of the gene signature and CTLA4 alone
were compared, the gene signature seemed to have only
a slightly stronger predictive power (concordance
probability estimate [CPE] 0.62 versus 0.59, p Z 0.03;
Akaike’s information criterion [AIC] 244 versus 241,
p Z 0.03).
4. Discussion
BTCs are recognised to be inflammatory cancers with
associated activation of the immune system
[16,18,24e26]. Loss of immune response in BTCs is
associated with lack of peritumoural inflammatory
infiltrate and poorer survival [27,28]. It is reasonable to
hypothesise that the activation of immune-escaping
phenomena can favour tumour relapse after surgical
resection [29e31]. In this study, we characterised the
immune response of resected BTCs and observed that
the deregulation of immunomodulatory transcripts in
peritumoural areas can create an immunosuppressive
milieu that facilitates tumour relapse, likely through
the activation of the CTLA4 axis. We focussed our
validation on CTLA4 because it is a target of immu-
nomodulatory drugs currently available and may
represent an ideal target for therapeutic interventions.
Nonetheless, treatment with CTLA4 inhibitors looked
promising in isolated cases of BTCs [32]. Recent studies
provide evidence for the benefit of adjuvant treatment
in resected BTCs [9]. Given post-operative treatment
seems to be effective in improving long-term outcome,
optimisation of adjuvant therapy may be a good
strategy to increase the cure rate of this otherwise
deadly disease. Our data suggest that it may be worth
exploring the role of immunotherapy in the adjuvantsetting of BTCs as a means of preventing recurrence by
re-addressing the immune response. Furthermore,
immunomodulatory drugs targeting CTLA4, given
post-operatively to melanoma patients, appear to pro-
vide significant benefit [33]. The BILCAP study has
shown that median RFS is improved from 18 to 25
months [9]. Thus, it is likely that a subgroup of patients
may get higher benefit from additional chemotherapy;
thus, identification of prognostic factors that indicate
the risk of relapse may aid patient selection. In our
data, we observed that the expression of CTLA4 in the
peritumoural area seems to have a high prognostic
value, as it reflects the capacity of the host immune
system to react against the tumour. Extraction of RNA
from the AT may be more challenging in comparison to
TT. However, modern techniques, such as nCounter
analysis, enable the assessment of mRNA transcripts
from small amounts of RNA obtained from formalin-
fixed paraffin-embedded tissues [34]. This has already
allowed gene expression profiling to guide adjuvant
chemotherapy in other solid tumours such as breast
cancer [35,36].
Emerging evidence is supporting the role of Tregs in
shaping tumour sensitivity to chemotherapy. Low
stromal Treg density is associated with better responses
to chemo-radiotherapy [10], and the depletion of
circulating Treg following chemotherapy is associated
with better outcomes [11]. CTLA4 is expressed on the
surface of Tregs and has to bind to CD80 on antigen-
presenting cells to exert inhibitory effects on cytotoxic
cells [24]. Thus, it is likely that the association we have
observed between strong CD80 expression and resis-
tance to adjuvant chemotherapy may reflect the
enrichment of activated Tregs in the microenvironment,
which inhibit response to chemotherapy. The assess-
ment of CD80 by IHC has two advantages: 1) allows
Fig. 3. Cluster of differentiation 80 (CD80) protein expression and prognosis. (A) The presence of CD80-positive cells in the adjacent tissue
(AT) was assessed by immunohistochemistry (IHC). Examples of CD80-poor and CD80-rich biliary tract cancer cases are shown.
(B) CD80 protein expression was assessed by IHC in the AT of the entire set (nZ 53). Cases were divided according to protein expression
of CD80 in the AT (þþþ versus /þ/þþ). (C) The same analysis was performed in the cohort receiving post-operative observation or
adjuvant chemotherapy. In the latter median relapse-free survival (RFS) was 16.27 months in strong (þþþ) CD80 (nZ 11) whereas it was
28.8 months in the other (/þ/þþ) group (nZ 9). (D) CD80 expression was assessed by IHC in the AT (nZ 53). In strong CD80 cases
median RFS was 16.27 months in the adjuvant group compared to 29.93 months in the observation group. In the cases with negative/mild
expression of CD80, adjuvant chemotherapy improved median RFS from 17.23 months to 28.8 months (non-significant).
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compared to differentiation just in two groups and 2) is
a standardised method that can be easily reproduced
and taken into clinical practice, provided confirmationand validation of our findings are achieved in larger
prospective cohorts.
Our study suggests that the microenvironment of
BTCs is characterised by a deregulation of the immune
M. Ghidini et al. / European Journal of Cancer 86 (2017) 158e165164system towards an immunosuppressive phenotype and
may include activation of Tregs that confer aggressive-
ness and chemo-resistance. Owing to the limited number
of patients in our study, definitive conclusions cannot be
made. However, we believe that these observations
deserve further validation in large, prospective studies to
assess the role of immunomodulatory transcripts as
prognostic factors in resected BTCs and support the
investigation of immunomodulatory drugs in BTCs.
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